Innovator. Advocate.Together with patients, on a mission to advance transformative treatments for people living with serious and rare diseases.
Our Commitment
At Akcea, we’re on a mission to transform the treatment of unaddressed or under-addressed serious and rare diseases with leading-edge, RNA-targeted medicines. Whether you’re a patient living with a serious condition, or a physician whose patient desperately needs a therapy, we know you’re counting on us, and it fuels our unwavering commitment to be a partner to the community through innovation.
Our Programs
Cardiometabolic Lipid Disorders and Volanesorsen
There is a significant need for new therapies targeting the protein and lipid risk factors associated with these serious, complex diseases. Our registrational-stage therapy volanesorsen has been developed for two of these diseases: FCS and FPL.
Hereditary Transthyretin (TTR) Amyloidosis and Inotersen
TTR amyloidosis (ATTR) is a rare, progressive and fatal genetic disease that currently only has limited treatment options that do not treat the underlying cause of disease. Inotersen for hATTR amyloidosis is currently under regulatory review for marketing authorization by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).
News
June 13, 2018
Akcea Announces Completion of Landmark Study to Assess Disease Burden in People Living with FCS
June 05, 2018
Akcea Therapeutics Appoints Industry Leader Dr. Richard Moscicki to Board of Directors
Learning about hereditary transthyretin (TTR) amyloidosis
TTR amyloidosis (ATTR) is a rare, progressive and fatal genetic disease that currently only has limited treatment options that do not treat the underlying cause of disease.
Visit hattrchangethecourse.comLearning about familial chylomicronemia syndrome (FCS)
FCS is a severe and rare disease caused by an enzyme deficiency that leads to the buildup of chylomicrons and a high risk of life-threatening pancreatitis
Visit FCSFocus.com
